Anti-infective drug development company Appili Therapeutics is set to receive funding to support the development of a new antibiotic to treat gram-negative infections.

The additional $400,000 funding from the National Research Council of Canada Industrial Research Assistance Programme (NRC-IRAP) will bring IRAP support for this project to a total of up to $759,000.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Appili will use the funding to develop ATI-1503, an antibiotic targeting, drug-resistant, gram-negative bacteria, including Klebsiella pneumoniae, Acinetobactor baumannii and Pseudomonas aeruginosa.

These superbugs cause potentially deadly infections such as pneumonia and blood infections.

ATI-1503 is a naturally occurring, synthetic version of the Negamycin antibiotic.

Appili Therapeutics CFO Kimberly Stephens said: “Doctors are fast running out of treatment options and IRAP funding is an important part of our financial strategy for helping Appili develop a new antibiotic that can treat these deadly diseases.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“Appili’s drug development team will use the funding to employ latest X-ray crystallography to visualise the exact structure of ATI-1503 binding to the bacterial target.”

Appili’s drug development team will use the funding to employ latest X-ray crystallography to visualise the exact structure of ATI-1503 binding to the bacterial target.

The potency of ATI-1503 against these drug-resistant infections will be systematically optimised with the help of the crystal structure data.

The bacteria with two cellular walls Klebsiella pneumoniae, Acinetobactor baumannii, and Pseudomonas aeruginosa make it hard for antibiotics to penetrate.

ATI-1503 has the ability to treat these superbugs as it penetrates the double exterior membranes and attacks the protein generating machinery of bacteria.

The bacteria are resistant to most antibiotics and thrive in hospitals and residential care facilities, infecting already vulnerable patients.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact